Issue #20 | Conflict, Ceasefire & a $3.4b Exit

ASX - Top Winner & Loser
Deals Down Under - I-MED's $3.4b Exit
Global Markets - Iran Ceasefire Watch
Other News - Aussie Politics, Sport and Culture

The ASX 200 ended May on a high, climbing 1.6% on Friday, recovering from a rough Thursday and finishing the week up 0.9%, and the month up 0.8%. The catalyst was a tentative 60-day ceasefire between the US and Iran, which eased the market’s uneasiness, sent Brent crude down 0.9% to $US92.87, and lifted risk appetite across the board. Materials led the charge as gold rebounded to around $US4,500 an ounce after hitting a two-month low the day prior – a sign that investors weren't fully convinced the ceasefire holds.

The week’s best performer

Electro Optic Systems (ASX:EOS) +25.34%

EOS surged this week after announcing two high-profile board appointments. Retired Air Vice-Marshal Catherine Roberts and retired Major General Kathryn Toohey, who sits on the board of Austal Ltd, joined as Non-Executive Directors. For a company scaling its global counter-drone and space businesses, adding two former senior ADF figures sends a strong credibility signal. The move landed against an already bullish backdrop since EOS shares had climbed from below $9 just a week prior, with stockbroker, Bell Potter carrying a $10.60 price target on the stock. 

This week's worst performer

ASX Limited (ASX:ASX) -22.30%

ASX Limited, the company that runs the Australian stock exchange, had a tough week after releasing a financial guidance update that rattled investors. FY2027 total expense growth is forecast at 18–21%, driven by technology modernisation, remediation work, and costs tied to an ASIC inquiry. Capital expenditure is also on the rise, climbing from $100–120 million this year to $170–190 million by FY2028. Income investors got hit too, with dividends expected to sit at the bottom end of the payout range over at least the next two payments. The underlying revenue numbers were fine, but the spending trajectory wasn't. 

Australia's biggest radiology network just found a new owner – and it wasn't Australian.

Permira, the London-based buyout firm that acquired I-MED Radiology seven years ago, this week agreed to sell the business to Jardine Matheson for $3.4 billion – ending what had been shaping up as one of the year's most anticipated IPOs. The deal gives Jardine Matheson 100 per cent ownership of the largest radiology business in the Asia Pacific region, with 250 clinics across Australia and New Zealand generating $1.5 billion in revenue and $260 million EBITDA last financial year.

Jardine Matheson is a 194-year-old London-listed conglomerate with a portfolio spanning real estate, retail and hospitality across Asia. I-MED is its first major global healthcare investment and is a meaningful pivot for a business better known for shopping centres, rather than CT scanners. CEO Lincoln Pan is expected to retain I-MED's existing management team, signalling the play is long-term ownership rather than a quick restructure.

For Permira, it draws a line under a two-year exit process that included two failed auction rounds where Macquarie Asset Management and Bain Capital both made offers that fell short, before Jefferies' Michael Stock convinced his client to run a dual-track process exploring both an IPO and a trade sale simultaneously. The private sale evidently won.

I-MED is the third major IPO candidate to slip through the ASX's fingers this year, joining La Trobe Financial and Estia Health as businesses that chose a private exit over a public listing. All three had run dual-track processes. All three sold privately in the end, a quiet but telling signal about where vendors see more certainty right now.

The acquisition also includes I-MED's stake in Harrison.AI, the medical imaging AI company, which adds a technology dimension to what is otherwise a bricks-and-mortar healthcare deal. For a conglomerate trying to establish itself in healthcare for the first time, that's not a bad place to start.

The global energy sector and macro markets are closely watching Washington this week, as US President Donald Trump held a crucial Situation Room meeting to make a "final determination" on a tentative deal to pause the US-Iran war. The proposed framework outlines a 60-day ceasefire extension, under which Iran clears sea mines within 30 days, the US lifts its naval blockade in phases, oil sanctions are relaxed, and negotiations on Tehran's 440kg enriched uranium stockpile begin. The critical market catalyst is the proposed reopening of the Strait of Hormuz, which carries roughly 20% of global petroleum liquids and has been effectively blocked since hostilities began, driving WTI crude back above $100 per barrel. 

Trump concluded the Situation Room meeting without a decision, stating he is "not satisfied" with Iran's terms. Tehran confirmed nothing is finalised, with a $24 billion frozen asset demand, half payable upfront, and the uranium stockpile remaining live sticking points. Trump further complicated talks by demanding Saudi Arabia, Turkey, Egypt, and Jordan expand the Abraham Accords as a precondition to any deal.

Away from the negotiating table, hostilities have not stopped. Despite the fragile ceasefire, US forces struck Bandar Abbas in what has been described as defensive action to maintain the truce, targeting missile sites and Iranian boats attempting to mine the shipping lanes, drawing an IRGC ballistic missile retaliatory strike on a US base in Kuwait. 

For Australian markets, even a successful deal won't be a clean fix. The ASX 200 is down 7% since the war began in late February, lagging Wall Street, Tokyo, and Seoul. Although the ASX bounced 0.9% Friday on ceasefire reports, Wilson Asset Management's Damien Boey says the underperformance is as much domestic as geopolitical with the RBA having raised rates three times this year to 4.35%, with another hike priced in before Christmas. "Equity market investors probably need to brace for more turbulence," he said. JPMorgan's Kerry Craig argues a durable recovery needs Chinese fiscal stimulus to reignite commodity demand and enough disinflation to convince the RBA to pause.

For now, the ASX is stuck between a war it can't control and an RBA that won't budge.

Thanks for reading Capital Down Under till the end! If you enjoyed this week's issue, feel free to forward it to a friend — we'd really appreciate it.

Also, if you had any thoughts, tips or ideas for next week, just hit reply.